NO20060631L - Fast dispersjon av takrolimus - Google Patents
Fast dispersjon av takrolimusInfo
- Publication number
- NO20060631L NO20060631L NO20060631A NO20060631A NO20060631L NO 20060631 L NO20060631 L NO 20060631L NO 20060631 A NO20060631 A NO 20060631A NO 20060631 A NO20060631 A NO 20060631A NO 20060631 L NO20060631 L NO 20060631L
- Authority
- NO
- Norway
- Prior art keywords
- tacrolimus
- solid dispersion
- carrier
- solid
- bioavailability
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
- A61K38/13—Cyclosporins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
- A61K9/1676—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface having a drug-free core with discrete complete coating layer containing drug
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
Abstract
Oppfinnelsen angår en bærer for en fast dispersjon av takrolimus, som fremstilles ved anvendelse av en fast surfaktant med en HLB-verdi høyere enn eller lik ca. 7. Surfaktantene har funksjon som bærer og funksjon som oppløsningsfremmer samtidig. Som et resultat forbedres oppløsningshastigheten til takrolimus og den orale absorpsjonsevnen og biotilgjengeligheten kan økes basert på den raske medikamentfrigivelsen.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR20030046550 | 2003-07-09 | ||
PCT/KR2004/001684 WO2005004848A1 (en) | 2003-07-09 | 2004-07-09 | The solid dispersion of tacrolimus |
Publications (1)
Publication Number | Publication Date |
---|---|
NO20060631L true NO20060631L (no) | 2006-04-05 |
Family
ID=36587202
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20060631A NO20060631L (no) | 2003-07-09 | 2006-02-09 | Fast dispersjon av takrolimus |
Country Status (9)
Country | Link |
---|---|
US (1) | US20060177500A1 (no) |
EP (1) | EP1641437A4 (no) |
JP (1) | JP2007527383A (no) |
KR (1) | KR100486016B1 (no) |
CN (1) | CN1819817A (no) |
BR (1) | BRPI0412329A (no) |
MX (1) | MXPA06000370A (no) |
NO (1) | NO20060631L (no) |
WO (1) | WO2005004848A1 (no) |
Families Citing this family (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2004267910B2 (en) | 2003-08-29 | 2011-01-06 | Veloxis Pharmaceuticals, Inc. | Solid dispersions comprising tacrolimus |
JP4903568B2 (ja) * | 2003-08-29 | 2012-03-28 | ベロクシス ファーマシューティカルズ エー/エス | タクロリムスを含む固体分散体 |
KR100539706B1 (ko) * | 2005-01-25 | 2005-12-28 | 지엘팜텍 주식회사 | 타크로리무스 및 장용성 고분자를 함유하는 고체분산체 |
KR100678824B1 (ko) * | 2005-02-04 | 2007-02-05 | 한미약품 주식회사 | 용해성이 증가된 무정형 타크로리무스 고체분산체 및 이를포함하는 약제학적 조성물 |
KR100711220B1 (ko) * | 2005-06-14 | 2007-04-24 | 삼천당제약주식회사 | 타크로리무스를 함유하는 경구용 조성물 및 그의 제조방법 |
KR100693461B1 (ko) * | 2005-07-29 | 2007-03-12 | 동국제약 주식회사 | 마크로라이드계 항생물질을 유효성분으로 함유하는약제학적 조성물 및 이의 제조방법과, 상기 약제학적조성물을 함유하는 서방성 제제 |
MXPA05010457A (es) * | 2005-09-28 | 2007-03-27 | Fernando Ahumada Ayala | Preparacion para el tratamiento de enfermedades inflamatorias de la piel, que contiene tacrolimus. |
DE102005047561A1 (de) * | 2005-10-04 | 2007-04-05 | Bayer Healthcare Ag | Feste, oral applizierbare pharmazeutische Darreichungsformen mit schneller Wirkstofffreisetzung |
CA2664315C (en) | 2006-09-15 | 2016-01-19 | Echo Pharmaceuticals B.V. | Dosage unit for sublingual, buccal or oral administration of water-insoluble pharmaceutically active substances |
US20100034888A1 (en) * | 2006-09-15 | 2010-02-11 | Hubert Clemens Pellikaan | Granulate containing a pharmaceutically active substance and method for its manufacture |
JPWO2008041553A1 (ja) * | 2006-09-26 | 2010-02-04 | アステラス製薬株式会社 | タクロリムス徐放性製剤 |
WO2008127746A1 (en) | 2007-01-10 | 2008-10-23 | Board Of Regents The University Of Texas System | Enhanced delivery of immunosuppressive drug compositions for pulmonary delivery |
LT2167033T (lt) | 2007-05-30 | 2017-08-10 | Veloxis Pharmaceuticals A/S | Kartą per dieną vartojama geriamoji vaisto forma, apimanti takrolimą |
DK2400950T3 (da) | 2009-02-26 | 2019-07-29 | Glaxo Group Ltd | Farmaceutiske formuleringer omfattende 4-{(1 r)-2-[(6-{2-[(2,6-dichlorbenzyl)oxy]ethoxy}hexyl)amino]-1-hydroxyethyl}-2-(hydroxymethyl)phenol |
GB0921075D0 (en) | 2009-12-01 | 2010-01-13 | Glaxo Group Ltd | Novel combination of the therapeutic agents |
PT2575769T (pt) | 2010-02-17 | 2016-09-22 | Veloxis Pharmaceuticals As | Composição de tacrolímus estabilizada |
KR20130028824A (ko) * | 2011-09-09 | 2013-03-20 | 주식회사 삼양바이오팜 | 타크로리무스를 포함하는 고체 분산체 및 이의 제조방법 |
WO2013169101A1 (en) | 2012-05-07 | 2013-11-14 | Echo Pharmaceuticals B.V. | Granulate containing cannabinoid, method for its manufacture and oral dosage unit comprising such granulate |
CN104415054A (zh) * | 2013-08-20 | 2015-03-18 | 哈药集团三精制药股份有限公司 | 一种速释复方氨酚烷胺片的制备方法 |
CN110639020B (zh) * | 2019-08-15 | 2022-07-08 | 浙江工业大学 | 一种固体分散体基质及其制备方法和应用 |
CN113577032A (zh) * | 2021-08-27 | 2021-11-02 | 国药集团川抗制药有限公司 | 他克莫司固体分散体的制备方法、速释药物组合物和应用 |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4894366A (en) * | 1984-12-03 | 1990-01-16 | Fujisawa Pharmaceutical Company, Ltd. | Tricyclo compounds, a process for their production and a pharmaceutical composition containing the same |
GB8608080D0 (en) * | 1986-04-02 | 1986-05-08 | Fujisawa Pharmaceutical Co | Solid dispersion composition |
BE1009856A5 (fr) * | 1995-07-14 | 1997-10-07 | Sandoz Sa | Composition pharmaceutique sous la forme d'une dispersion solide comprenant un macrolide et un vehicule. |
CZ267796A3 (cs) * | 1996-09-12 | 1998-04-15 | Galena A.S. | Léčivé přípravky, zejména pro vnitřní aplikaci, ve formě samomikroemulgujících terapeutických systémů |
TW426516B (en) * | 1996-12-06 | 2001-03-21 | Fujisawa Pharmaceutical Co | An oral pharmaceutical composition in solid dispersion containing water-insoluble tricyclic compounds |
EP0978288A4 (en) * | 1997-04-11 | 2006-07-12 | Astellas Pharma Inc | DRUG COMPOSITION |
TR200002771T2 (tr) * | 1998-03-26 | 2001-02-21 | Fujisawa Pharmaceutical Co.,Ltd. | Devamlı salımı olan preparatlar |
US6248363B1 (en) * | 1999-11-23 | 2001-06-19 | Lipocine, Inc. | Solid carriers for improved delivery of active ingredients in pharmaceutical compositions |
US20010036959A1 (en) * | 2000-04-03 | 2001-11-01 | Gabel Rolf Dieter | Carvedilol-hydrophilic solutions |
AU2004267910B2 (en) * | 2003-08-29 | 2011-01-06 | Veloxis Pharmaceuticals, Inc. | Solid dispersions comprising tacrolimus |
-
2004
- 2004-07-09 BR BRPI0412329-8A patent/BRPI0412329A/pt not_active IP Right Cessation
- 2004-07-09 WO PCT/KR2004/001684 patent/WO2005004848A1/en active Application Filing
- 2004-07-09 EP EP04774097A patent/EP1641437A4/en not_active Withdrawn
- 2004-07-09 KR KR10-2004-0053269A patent/KR100486016B1/ko active IP Right Grant
- 2004-07-09 CN CNA2004800193916A patent/CN1819817A/zh active Pending
- 2004-07-09 MX MXPA06000370A patent/MXPA06000370A/es unknown
- 2004-07-09 US US10/563,972 patent/US20060177500A1/en not_active Abandoned
- 2004-07-09 JP JP2006518554A patent/JP2007527383A/ja active Pending
-
2006
- 2006-02-09 NO NO20060631A patent/NO20060631L/no not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
BRPI0412329A (pt) | 2006-09-05 |
MXPA06000370A (es) | 2006-03-28 |
WO2005004848A1 (en) | 2005-01-20 |
CN1819817A (zh) | 2006-08-16 |
KR20050007173A (ko) | 2005-01-17 |
EP1641437A4 (en) | 2009-06-03 |
EP1641437A1 (en) | 2006-04-05 |
JP2007527383A (ja) | 2007-09-27 |
US20060177500A1 (en) | 2006-08-10 |
KR100486016B1 (ko) | 2005-04-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO20060631L (no) | Fast dispersjon av takrolimus | |
ATE434639T1 (de) | Wässrige dispersionen von silikon-polyether- blockcopolymeren | |
WO2005011592A3 (en) | Substituted indazole-o-glucosides | |
WO2005012243A3 (en) | Substituted indole-o-glucosides | |
WO2003093290A3 (en) | Nucleoside derivatives for treating hepatitis c virus infection | |
WO2004028481A3 (en) | Nucleoside derivatives for treating hepatitis c virus infection | |
WO2006039668A3 (en) | 3-ether and 3-thioether substituted cyclosporin derivatives for the treatment and prevention of hepatitis c infection | |
EA200901186A1 (ru) | S-ТРИАЗОЛИЛ-α-МЕРКАПТОАЦЕТАНИЛИДЫ КАК ИНГИБИТОРЫ ОБРАТНОЙ ТРАНСКРИПТАЗЫ ВИЧ | |
EP1924593B8 (en) | Hcv ns3 protease inhibitors | |
DK1670433T3 (da) | Transdermal farmaceutisk formulering til mindskelse af hudrester | |
WO2004011478A3 (en) | Anti-viral 7-deaza d-nucleosides and uses thereof | |
DK1792927T3 (da) | Ny blokcopolymer, micelletilberedning og anticancermiddel indeholdende samme som aktiv ingrediens | |
NO20070751L (no) | Inhibitorer av HCV-replifikasjon | |
NO20092053L (no) | HCV NS3-proteaseinhibitorer | |
TW200642689A (en) | Immunosuppressive agent and anti-tumor agent comprising heterocyclic compound as active ingredient | |
WO2007092645A3 (en) | Novel hcv inhibitor combinations and methods | |
WO2005123093A3 (en) | Ophthalmic formulations including selective alpha 1 antagonists | |
WO2003097794A3 (en) | Universal-tagged oligonucleotide primers and methods of use | |
WO2006138418A3 (en) | Improvement of cognitive performance with sirtuin activators | |
WO2004014926A8 (fr) | Alcoxyamines issues de nitroxydes βετα-phosphores, leur utilisation en polymerisation radicalaire | |
NO20054776L (no) | Kontrollert frigivelsessystem som inneholder sakkaroseacctatisobutyrat | |
NO20050801L (no) | Prodrug av protonpumpe inhibitorer | |
WO2004002940A8 (en) | Inhibitors of hcv ns5b polymerase | |
NO20024891L (no) | Farmasöytiske sammensetninger | |
NO20050346L (no) | Nitro-oksyderivater av syklooksygenase-2-inhibitorer |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC2A | Withdrawal, rejection or dismissal of laid open patent application |